Resalis Therapeutics is a biopharma company focused on the development of oligonucleotide anti-sense therapies to treat metabolic disorders, including MAFLD/NAFLD/NASH, obesity, and cancer. The company leverages on the scientific research of a team of internationally renowned scientists.
Pressured by unmet clinical needs affecting tenths of millions of patients in the world, Resalis Therapeutics is advancing its pipeline of first-in-class anti-miRNA compounds toward clinical validation, supported by robust preclinical evidence generated at Beth Israel Deaconess Medical Center (Harvard Medical School, Boston – US) and Aalborg University (Copenhagen, Denmark).
https://www.resalistherapeutics.com/
Date of investment May, 2021
Offices Torino, Italy
Eva Castagnetti
Chief Executive Officer
Riccardo Panella
Scientific Founder - BoD Member
